Literature DB >> 12658725

Targeting peptides and positron emission tomography.

Hans Lundqvist1, Vladimir Tolmachev.   

Abstract

Biologically active peptides have during the last decades made their way into conventional nuclear medicine diagnosis using single photon emission computed tomography (SPECT) and gamma-camera. Several clinical trails are also investigating the role of radiolabeled peptides for targeting radionuclide therapy. This has raised the question as to whether positron emission tomography (PET) can be used in order to obtain better quantitative information of the peptide distribution in tumor and healthy organs, i.e., to get a better dosimetry. Positron emitting analogs of the therapeutic radionuclides used have been produced and successfully applied in peptide pharmacokinetic measurements with PET. But the recent boom in (18)FDG-PET ((18)FDG = [(18)F]2-deoxy-2-fluoro-D-glucose), and with this a worldwide increasing number of PET systems, has also inspired several research groups to hunt for alternative labels to be used for peptide diagnostics and PET. The rapid kinetic of short peptides agrees well with the short half-lives of standard PET nuclides like (11)C and (18)F. Especially, (18)F appears to be excellent for labeling bioactive peptides due to its favorable physical and nuclear characteristics. However, with present techniques labeling peptides with (18)F is laborious and time-consuming, and is not yet a clinical alternative. Other halogens like (75, 76)Br and (124)I are, from the chemical point of view, easier to apply. But an even better labeling alternative may be positron emitting metal ions like (55)Co, (68)Ga, and (110m)In since they tend to give better intracellular retention and thus a better signal-to-background ratio than the halogen labels. The main drawback with these radionuclides is that they are not readily available. Some of these radionuclides also emit gamma in their decay that may affect the measuring properties of the PET equipment. This article reviews mainly the present situation of production and use of nonconventional positron emitters for peptide labeling. Copyright 2003 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12658725     DOI: 10.1002/bip.10348

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  7 in total

1.  Noninvasive detection of tumor-infiltrating T cells by PET reporter imaging.

Authors:  Melissa N McCracken; Dimitrios N Vatakis; Dhaval Dixit; Jami McLaughlin; Jerome A Zack; Owen N Witte
Journal:  J Clin Invest       Date:  2015-03-30       Impact factor: 14.808

2.  Comparison of 18F PET and 99mTc SPECT imaging in phantoms and in tumored mice.

Authors:  Dengfeng Cheng; Yi Wang; Xinrong Liu; P Hendrik Pretorius; Minmin Liang; Mary Rusckowski; Donald J Hnatowich
Journal:  Bioconjug Chem       Date:  2010-08-18       Impact factor: 4.774

Review 3.  Whole animal imaging.

Authors:  Gurpreet Singh Sandhu; Luis Solorio; Ann-Marie Broome; Nicolas Salem; Jeff Kolthammer; Tejas Shah; Chris Flask; Jeffrey L Duerk
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2010 Jul-Aug

4.  Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging.

Authors:  Thuy A Tran; Daniel Rosik; Lars Abrahmsén; Mattias Sandström; Anna Sjöberg; Helena Wållberg; Sara Ahlgren; Anna Orlova; Vladimir Tolmachev
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-06       Impact factor: 9.236

5.  Proof of principle for the use of 11C-labelled peptides in tumour diagnosis with PET.

Authors:  G Henriksen; M Schottelius; T Poethko; A Hauser; I Wolf; M Schwaiger; Hans-Jürgen Wester
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-10       Impact factor: 9.236

6.  Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys61]-Z HER2:2395(-Cys) affibody molecule for targeting of HER2-expressing tumors.

Authors:  Helena Wållberg; Sara Ahlgren; Charles Widström; Anna Orlova
Journal:  Mol Imaging Biol       Date:  2009-06-26       Impact factor: 3.488

7.  F-18 labeled vasoactive intestinal peptide analogue in the PET imaging of colon carcinoma in nude mice.

Authors:  Dengfeng Cheng; Yuxia Liu; Hua Shen; Lifang Pang; Duanzhi Yin; Yongxian Wang; Shanqun Li; Hongcheng Shi
Journal:  Biomed Res Int       Date:  2013-12-26       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.